CARISMA Therapeutics Inc has a consensus price target of $9.2 based on the ratings of 5 analysts. The high is $12 issued by Evercore ISI Group on July 6, 2023. The low is $6 issued by BTIG on April 11, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on June 28, 2024, June 26, 2024, and May 17, 2024, respectively. With an average price target of $8 between HC Wainwright & Co., there's an implied 640.74% upside for CARISMA Therapeutics Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
06/28/2024 | Buy Now | 640.74% | HC Wainwright & Co. | Mitchell Kapoor | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
06/26/2024 | Buy Now | 640.74% | HC Wainwright & Co. | Mitchell Kapoor | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
05/17/2024 | Buy Now | 640.74% | HC Wainwright & Co. | Mitchell Kapoor | → $8 | Reiterates | Buy → Buy | Get Alert |
05/10/2024 | Buy Now | 640.74% | HC Wainwright & Co. | Mitchell Kapoor | $9 → $8 | Maintains | Buy | Get Alert |
04/11/2024 | Buy Now | 455.56% | BTIG | Justin Zelin | → $6 | Initiates | → Buy | Get Alert |
04/02/2024 | Buy Now | 733.33% | HC Wainwright & Co. | Mitchell Kapoor | $11 → $9 | Maintains | Buy | Get Alert |
11/29/2023 | Buy Now | 918.52% | HC Wainwright & Co. | Mitchell Kapoor | → $11 | Reiterates | Buy → Buy | Get Alert |
10/03/2023 | Buy Now | 825.93% | Capital One | Naureen Quibria | → $10 | Initiates | → Overweight | Get Alert |
09/06/2023 | Buy Now | 918.52% | HC Wainwright & Co. | Mitchell Kapoor | → $11 | Reiterates | Buy → Buy | Get Alert |
08/11/2023 | Buy Now | 918.52% | HC Wainwright & Co. | Mitchell Kapoor | $10 → $11 | Maintains | Buy | Get Alert |
07/06/2023 | Buy Now | 1011.11% | Evercore ISI Group | Liisa Bayko | → $12 | Initiates | → Outperform | Get Alert |
06/29/2023 | Buy Now | 825.93% | HC Wainwright & Co. | Mitchell Kapoor | → $10 | Reiterates | Buy → Buy | Get Alert |
06/28/2023 | Buy Now | 825.93% | Baird | Jack Allen | → $10 | Reiterates | Outperform → Outperform | Get Alert |
05/24/2023 | Buy Now | 825.93% | HC Wainwright & Co. | Mitchell Kapoor | → $10 | Initiates | → Buy | Get Alert |
04/14/2023 | Buy Now | 825.93% | Baird | Jack Allen | → $10 | Initiates | → Outperform | Get Alert |
The latest price target for CARISMA Therapeutics (NASDAQ:CARM) was reported by HC Wainwright & Co. on June 28, 2024. The analyst firm set a price target for $8.00 expecting CARM to rise to within 12 months (a possible 640.74% upside). 10 analyst firms have reported ratings in the last year.
The latest analyst rating for CARISMA Therapeutics (NASDAQ:CARM) was provided by HC Wainwright & Co., and CARISMA Therapeutics reiterated their buy rating.
There is no last upgrade for CARISMA Therapeutics
There is no last downgrade for CARISMA Therapeutics.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CARISMA Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CARISMA Therapeutics was filed on June 28, 2024 so you should expect the next rating to be made available sometime around June 28, 2025.
While ratings are subjective and will change, the latest CARISMA Therapeutics (CARM) rating was a reiterated with a price target of $8.00 to $8.00. The current price CARISMA Therapeutics (CARM) is trading at is $1.08, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.